A 38-yeаr-оld mаle presents fоr treаtment оf a second episode of Major Depressive Disorder (MDD). He has a significant family history of Type 2 Diabetes and a personal history of metabolic syndrome, with a current BMI of 31.0. During the evaluation, the patient emphasizes that he is "very concerned about adding more weight" and specifically requests a medication that is least likely to impact his metabolism. While Selective Serotonin Reuptake Inhibitors (SSRIs) are generally preferred as first-line treatment for MDD, the Psychiatric-Mental Health Nurse Practitioner (PMHNP) knows that one specific medication in this class is significantly more likely to cause treatment-emergent weight gain and metabolic changes. Which of the following SSRIs should the PMHNP avoid in this patient?